CTA
BMRN icon

Carillon Tower Advisers’s BioMarin Pharmaceuticals BMRN Stock Holding History

Carillon Tower Advisers’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		$94.8M Buy
1,090,391
+814,739
+296% +$64.6M 0.58% 45
2020
Q3 		$21M Sell
275,652
-374,424
-58% -$37.9M 0.28% 129
2020
Q2 		$80.2M Buy
650,076
+102,476
+19% +$10.2M 0.62% 39
2020
Q1 		$46M Buy
547,600
+271,525
+98% +$23.4M 0.45% 63
2019
Q4 		$23.3M Buy
276,075
+196,650
+248% +$14.9M 0.16% 225
2019
Q3 		$5.35M Hold
79,425
– – 0.04% 384
2019
Q2 		$6.8M Sell
79,425
-53,450
-40% -$4.57M 0.05% 368
2019
Q1 		$11.8M Buy
132,875
+2,900
+2% +$269K 0.08% 315
2018
Q4 		$11.1M Buy
129,975
+29,000
+29% +$2.76M 0.09% 291
2018
Q3 		$9.79M Sell
100,975
-36,300
-26% -$3.62M 0.07% 339
2018
Q2 		$12.9M Sell
137,275
-142,223
-51% -$12.5M 0.1% 289
2018
Q1 		$21.6M Buy
279,498
+22,779
+9% +$1.95M 0.17% 200
2017
Q4 		$22.9K Buy
+256,719
New +$22.3M 0.24% 164

Other funds holding BMRN

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Carillon Tower Advisers's BMRN Position: Q4 2020 in Review

Carillon Tower Advisers increased its BioMarin Pharmaceuticals (BMRN) stake by 296% in Q4 2020, buying an estimated $64.6M and bringing the position to 1,090,391 shares worth $94.8M. The position accounts for 0.58% of the portfolio, ranked #45.

Carillon Tower Advisers first reported a position in BMRN in Q4 2017 and has held it in 13 quarters since. 537 funds tracked by Wall St. Rank hold BMRN as of Q4 2020.

  • Carillon Tower Advisers held 1,090,391 shares of BioMarin Pharmaceuticals worth $94.8M as of Q4 2020.
  • Carillon Tower Advisers bought 814,739 BioMarin Pharmaceuticals shares in Q4 2020, an estimated $64.6M.
  • BioMarin Pharmaceuticals made up 0.58% of Carillon Tower Advisers's portfolio in Q4 2020, its #45 holding.
  • Carillon Tower Advisers first reported a position in BioMarin Pharmaceuticals in Q4 2017 and has held it in 13 quarters since.
  • 537 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2020.

Based on Carillon Tower Advisers's 13F filing for Q4 2020, filed 12 Feb 2021.